Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

795.35 +7.16 (+0.91%)
Official Closing Price Updated: 5:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
Eli Lilly Beefs Up Neuro Pipeline With Addition Of Preclinical ALS, Dementia Prospect
QurAlis has entered an exclusive license agreement with Eli Lilly for QRL-204, an antisense oligonucleotide for ALS and other neurodegenerative diseases. QurAlis will receive $45 million upfront, with... 
Via Benzinga
Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results
Structure Therapeutics stock roses sharply Monday after the biotech company delivered "compelling" results for its weight-loss drug. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Eli Lilly and Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
Watch Out Wegovy: Here Comes Another Promising Anti-Obesity Candidate
The fight for dominance in the weight loss market is just getting started. 
Via The Motley Fool
Performance Comparison: Eli Lilly and Co And Competitors In Pharmaceuticals Industry
Via Benzinga
Could Eli Lilly Be the Next to Join the Trillion-Dollar Club?
Today, Eli Lilly's market value tops $700 billion. 
Via The Motley Fool
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments 
Via MarketBeat
4 Stocks Making New Highs Despite Market Weakness
While the market faced challenges on Friday, Birkenstock, NetApp, Eli Lilly, and Aflac showed notable strength by achieving new 52-week highs. 
Via MarketBeat
The Week Ahead: What's Next
The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle. 
Via Talk Markets
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
These two drugmakers have a lot more in common than their market-beating potential. 
Via The Motley Fool
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
These stocks are trading at sky-high valuations which could make them vulnerable to sell-offs. 
Via The Motley Fool
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Novo Nordisk Sues Additional US Clinics Against Fake Semaglutide Products Used For Weight Loss, Diabetes
Novo Nordisk has filed lawsuits against nine additional U.S. medical spas, wellness clinics, and pharmacies for selling impure or falsely labeled semaglutide products. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing
Sometimes the next big thing stocks to buy and hold are flying well under the radar. Here are three to consider. 
Via InvestorPlace
Aristocrats in Disguise: 3 Blue-Chip Stocks With Stealth Growth Potential
These blue-chip growth stocks provide the cornerstone for building a portfolio offerings a wealth of lucrative returns for years. 
Via InvestorPlace
Institutional Bets: 7 Stocks the Big Money Will Send Higher This Year
Institutions exert a powerful influence over these institutional favorite stocks that individual investors can benefit from in 2024. 
Via InvestorPlace
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk
New OZEM ETF offers investors exposure to weight-loss sector through top pharmaceutical companies Eli Lilly and Novo Nordisk, with potential for high growth but also risks. 
Via Benzinga
Topics ETFs
Weight Loss Drug Market To Rocket To $130B By 2030 With Eli Lilly, Novo Nordisk In Lead: Goldman Sachs
Goldman Sachs re-rated Eli Lilly and Novo Nordisk, citing potential for weight-loss drugs. Global sales expected to reach $130B by 2030. 
Via Benzinga
Urban Outfitters, Eli Lilly And 2 Other Stocks Insiders Are Selling
Via Benzinga
Blue-Chip Bubble Trouble: 7 Stocks to Short as Valuations Stretch to the Limit
Be careful with these overvalued blue-chip stocks, each of which is trading at a high multiple relative to its peers. 
Via InvestorPlace
Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker
NVIDIA Corp. (NASDAQ:NVDA) has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
FDA Conditionally Approves Eli Lilly's Thyroid Cancer Drug For Pediatric Patients With Certain Mutations
Accelerated FDA approval for Eli Lilly's selpercatinib (Retevmo) in pediatric patients aged 2+ with advanced/metastatic thyroid cancer & solid tumors carrying RET mutations or fusions. 
Via Benzinga
Exposures Product Safety
3 Sorry Pharma Stocks to Sell in May While You Still Can
Discover three pharma stocks to sell in May while you still can. Avoid these companies facing significant setbacks. 
Via InvestorPlace
Jim Cramer Recommends Buying Apple, Finds This Tech Stock 'Very Interesting'
On CNBC's "Mad Money Lightning Round," Jim Cramer said Apple Inc. is a "buy" after iPhone sales in China saw a 52% year-on-year increase. 
Via Benzinga
If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names
Between FDA approvals and product pipelines, it takes diligence to keep up with which biotech stocks to buy. 
Via InvestorPlace
Exposures Product Safety
Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply
The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increase from the previous forecast of $100 billion. This surge is attributed to... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Nvidia's Meteoric Rise: How Does It Compare To Other Market Rallies?
Bespoke analysts compared Nvidia to Microsoft, Amazon and Apple. Here's what the experts determined about the company's stock rally. 
Via Benzinga
A New Name in Weight Loss Drugs
Novo Nordisk and Eli Lilly have soared on the popularity of GLP-1 weight loss drugs. Now Hims & Hers is trying to get in on the action with a more available and affordable option. 
Via The Motley Fool
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.